<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25691649</PMID><DateCompleted><Year>2016</Year><Month>01</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-6596</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><Issue>5</Issue><PubDate><Year>2015</Year><Month>May</Month></PubDate></JournalIssue><Title>Antimicrobial agents and chemotherapy</Title><ISOAbbreviation>Antimicrob Agents Chemother</ISOAbbreviation></Journal><ArticleTitle>Discovery of itraconazole with broad-spectrum in vitro antienterovirus activity that targets nonstructural protein 3A.</ArticleTitle><Pagination><StartPage>2654</StartPage><EndPage>2665</EndPage><MedlinePgn>2654-65</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/AAC.05108-14</ELocationID><Abstract><AbstractText>There is currently no approved antiviral therapy for the prophylaxis or treatment of enterovirus infections, which remain a substantial threat to public health. To discover inhibitors that can be immediately repurposed for treatment of enterovirus infections, we developed a high-throughput screening assay that measures the cytopathic effect induced by enterovirus 71 (EV71) to screen an FDA-approved drug library. Itraconazole (ITZ), a triazole antifungal agent, was identified as an effective inhibitor of EV71 replication in the low-micromolar range (50% effective concentrations [EC50s], 1.15 &#x3bc;M). Besides EV71, the compound also inhibited other enteroviruses, including coxsackievirus A16, coxsackievirus B3, poliovirus 1, and enterovirus 68. Study of the mechanism of action by time-of-addition assay and transient-replicon assay revealed that ITZ targeted a step involved in RNA replication or polyprotein processing. We found that the mutations (G5213U and U5286C) conferring the resistance to the compound were in nonstructural protein 3A, and we confirmed the target amino acid substitutions (3A V51L and 3A V75A) using a reverse genetic approach. Interestingly, posaconazole, a new oral azole with a molecular structure similar to that of ITZ, also exhibited anti-EV71 activity. Moreover, ITZ-resistant viruses do not exhibit cross-resistance to posaconazole or the enviroxime-like compound GW5074, which also targets the 3A region, indicating that they may target a specific site(s) in viral genome. Although the protective activity of ITZ or posaconazole (alone or in combination with other antivirals) remains to be assessed in animal models, our findings may represent an opportunity to develop therapeutic interventions for enterovirus infection.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015, American Society for Microbiology. All Rights Reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Qianqian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Institute of Molecular Ecology and Evolution, SKLEC &amp; IECR, East China Normal University, Shanghai, China Unit of Anti-Infective Research, Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Shilin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Unit of Anti-Infective Research, Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Unit of Anti-Infective Research, Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Molecular Ecology and Evolution, SKLEC &amp; IECR, East China Normal University, Shanghai, China Unit of Anti-Infective Research, Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yizhuo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Unit of Anti-Infective Research, Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Guimei</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Molecular Ecology and Evolution, SKLEC &amp; IECR, East China Normal University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Shuyi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Molecular Ecology and Evolution, SKLEC &amp; IECR, East China Normal University, Shanghai, China syzhang@bio.ecnu.edu.cn raltmeyer@ips.ac.cn gangzou@ips.ac.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altmeyer</LastName><ForeName>Ralf</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Unit of Anti-Infective Research, Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China syzhang@bio.ecnu.edu.cn raltmeyer@ips.ac.cn gangzou@ips.ac.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Gang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Unit of Anti-Infective Research, Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China syzhang@bio.ecnu.edu.cn raltmeyer@ips.ac.cn gangzou@ips.ac.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>02</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Antimicrob Agents Chemother</MedlineTA><NlmUniqueID>0315061</NlmUniqueID><ISSNLinking>0066-4804</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>304NUG5GF4</RegistryNumber><NameOfSubstance UI="D017964">Itraconazole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017964" MajorTopicYN="N">Itraconazole</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25691649</ArticleId><ArticleId IdType="pmc">PMC4394834</ArticleId><ArticleId IdType="doi">10.1128/AAC.05108-14</ArticleId><ArticleId IdType="pii">AAC.05108-14</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pallansch M, Roos R. 2007. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses, p 840&#x2013;893. In Knipe D, Howley P (ed), Fields virology, 5th ed Lippincott Williams &amp; Wilkins, Philadelphia, PA.</Citation></Reference><Reference><Citation>Chang LY, Lin TY, Hsu KH, Huang YC, Lin KL, Hsueh C, Shih SR, Ning HC, Hwang MS, Wang HS, Lee CY. 1999. Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet 354:1682&#x2013;1686. doi:10.1016/S0140-6736(99)04434-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(99)04434-7</ArticleId><ArticleId IdType="pubmed">10568570</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu H, Nakashima K. 2014. Surveillance of hand, foot, and mouth disease for a vaccine. Lancet Infect Dis 14:262&#x2013;263. doi:10.1016/S1473-3099(13)70330-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(13)70330-X</ArticleId><ArticleId IdType="pubmed">24485992</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Macdonald NE, Smith JC, Cai K, Yu H, Li H, Lei C. 2014. Severe enterovirus type 71 nervous system infections in children in the shanghai region of china: clinical manifestations and implications for prevention and care. Pediatr Infect Dis J 33:482&#x2013;487. doi:10.1097/INF.0000000000000194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000000194</ArticleId><ArticleId IdType="pubmed">24732390</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn P, Stratov I, Nagarajan L, Davis S. 2001. Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clin Infect Dis 32:236&#x2013;242. doi:10.1086/318454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/318454</ArticleId><ArticleId IdType="pubmed">11170913</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber SA, Gauntt CJ, Sakkinen P. 1998. Enteroviruses and myocarditis: viral pathogenesis through replication, cytokine induction, and immunopathogenicity. Adv Virus Res 51:35&#x2013;80. doi:10.1016/S0065-3527(08)60783-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0065-3527(08)60783-6</ArticleId><ArticleId IdType="pubmed">9891585</ArticleId></ArticleIdList></Reference><Reference><Citation>Cihakova D, Rose NR. 2008. Pathogenesis of myocarditis and dilated cardiomyopathy. Adv Immunol 99:95&#x2013;114. doi:10.1016/S0065-2776(08)00604-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0065-2776(08)00604-4</ArticleId><ArticleId IdType="pubmed">19117533</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber S, Ramsingh AI. 2004. Coxsackievirus-induced pancreatitis. Viral Immunol 17:358&#x2013;369. doi:10.1089/vim.2004.17.358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vim.2004.17.358</ArticleId><ArticleId IdType="pubmed">15357902</ArticleId></ArticleIdList></Reference><Reference><Citation>Mena I, Fischer C, Gebhard JR, Perry CM, Harkins S, Whitton JL. 2000. Coxsackievirus infection of the pancreas: evaluation of receptor expression, pathogenesis, and immunopathology. Virology 271:276&#x2013;288. doi:10.1006/viro.2000.0332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.2000.0332</ArticleId><ArticleId IdType="pubmed">10860882</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberste MS, Maher K, Schnurr D, Flemister MR, Lovchik JC, Peters H, Sessions W, Kirk C, Chatterjee N, Fuller S, Hanauer JM, Pallansch MA. 2004. Enterovirus 68 is associated with respiratory illness and shares biological features with both the enteroviruses and the rhinoviruses. J Gen Virol 85:2577&#x2013;2584. doi:10.1099/vir.0.79925-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.79925-0</ArticleId><ArticleId IdType="pubmed">15302951</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirkovic RR, Kono R, Yin-Murphy M, Sohier R, Schmidt NJ, Melnick JL. 1973. Enterovirus type 70: the etiologic agent of pandemic acute haemorrhagic conjunctivitis. Bull World Health Organ 49:341&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2480954</ArticleId><ArticleId IdType="pubmed">4368683</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaida A, Kubo H, Sekiguchi J, Kohdera U, Togawa M, Shiomi M, Nishigaki T, Iritani N. 2011. Enterovirus 68 in children with acute respiratory tract infections, Osaka, Japan. Emerg Infect Dis 17:1494&#x2013;1497. doi:10.3201/eid1708.110028.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1708.110028</ArticleId><ArticleId IdType="pmc">PMC3381549</ArticleId><ArticleId IdType="pubmed">21801632</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephenson J. 2014. CDC tracking enterovirus D-68 outbreak causing severe respiratory illness in children in the Midwest. JAMA 312:1290. doi:10.1001/jama.2014.13256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2014.13256</ArticleId><ArticleId IdType="pubmed">25268426</ArticleId></ArticleIdList></Reference><Reference><Citation>Kung YA, Hung CT, Liu YC, Shih SR. 2014. Update on the development of enterovirus 71 vaccines. Expert Opin Biol Ther 14:1455&#x2013;1464. doi:10.1517/14712598.2014.935330.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14712598.2014.935330</ArticleId><ArticleId IdType="pubmed">24989170</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma AM, Vliegen I, De Clercq E, Neyts J. 2008. Selective inhibitors of picornavirus replication. Med Res Rev 28:823&#x2013;884. doi:10.1002/med.20125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.20125</ArticleId><ArticleId IdType="pubmed">18381747</ArticleId></ArticleIdList></Reference><Reference><Citation>Abzug MJ. 2014. The enteroviruses: problems in need of treatments. J Infect 68(Suppl 1):S108&#x2013;S114. doi:10.1016/j.jinf.2013.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2013.09.020</ArticleId><ArticleId IdType="pubmed">24119825</ArticleId></ArticleIdList></Reference><Reference><Citation>Wimmer E, Hellen CU, Cao X. 1993. Genetics of poliovirus. Annu Rev Genet 27:353&#x2013;436. doi:10.1146/annurev.ge.27.120193.002033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.ge.27.120193.002033</ArticleId><ArticleId IdType="pubmed">8122908</ArticleId></ArticleIdList></Reference><Reference><Citation>Norder H, De Palma AM, Selisko B, Costenaro L, Papageorgiou N, Arnan C, Coutard B, Lantez V, De Lamballerie X, Baronti C, Sola M, Tan J, Neyts J, Canard B, Coll M, Gorbalenya AE, Hilgenfeld R. 2011. Picornavirus non-structural proteins as targets for new anti-virals with broad activity. Antiviral Res 89:204&#x2013;218. doi:10.1016/j.antiviral.2010.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2010.12.007</ArticleId><ArticleId IdType="pubmed">21236302</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul AV, van Boom JH, Filippov D, Wimmer E. 1998. Protein-primed RNA synthesis by purified poliovirus RNA polymerase. Nature 393:280&#x2013;284. doi:10.1038/30529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/30529</ArticleId><ArticleId IdType="pubmed">9607767</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyoda H, Nicklin MJ, Murray MG, Anderson CW, Dunn JJ, Studier FW, Wimmer E. 1986. A second virus-encoded proteinase involved in proteolytic processing of poliovirus polyprotein. Cell 45:761&#x2013;770. doi:10.1016/0092-8674(86)90790-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(86)90790-7</ArticleId><ArticleId IdType="pubmed">3011278</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmenberg AC. 1990. Proteolytic processing of picornaviral polyprotein. Annu Rev Microbiol 44:603&#x2013;623. doi:10.1146/annurev.mi.44.100190.003131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.mi.44.100190.003131</ArticleId><ArticleId IdType="pubmed">2252396</ArticleId></ArticleIdList></Reference><Reference><Citation>Towner JS, Ho TV, Semler BL. 1996. Determinants of membrane association for poliovirus protein 3AB. J Biol Chem 271:26810&#x2013;26818. doi:10.1074/jbc.271.43.26810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.271.43.26810</ArticleId><ArticleId IdType="pubmed">8900162</ArticleId></ArticleIdList></Reference><Reference><Citation>Wikel JH, Paget CJ, DeLong DC, Nelson JD, Wu CY, Paschal JW, Dinner A, Templeton RJ, Chaney MO, Jones ND, Chamberlin JW. 1980. Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication. J Med Chem 23:368&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">6247489</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz BA, Vance LM. 1995. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. J Virol 69:4189&#x2013;4197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189156</ArticleId><ArticleId IdType="pubmed">7769678</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden FG, Gwaltney JM Jr. 1982. Prophylactic activity of intranasal enviroxime against experimentally induced rhinovirus type 39 infection. Antimicrob Agents Chemother 21:892&#x2013;897. doi:10.1128/AAC.21.6.892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.21.6.892</ArticleId><ArticleId IdType="pmc">PMC182041</ArticleId><ArticleId IdType="pubmed">6287928</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller FD, Monto AS, DeLong DC, Exelby A, Bryan ER, Srivastava S. 1985. Controlled trial of enviroxime against natural rhinovirus infections in a community. Antimicrob Agents Chemother 27:102&#x2013;106. doi:10.1128/AAC.27.1.102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.27.1.102</ArticleId><ArticleId IdType="pmc">PMC176213</ArticleId><ArticleId IdType="pubmed">2984980</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillpotts RJ, Wallace J, Tyrrell DA, Tagart VB. 1983. Therapeutic activity of enviroxime against rhinovirus infection in volunteers. Antimicrob Agents Chemother 23:671&#x2013;675. doi:10.1128/AAC.23.5.671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.23.5.671</ArticleId><ArticleId IdType="pmc">PMC184785</ArticleId><ArticleId IdType="pubmed">6870216</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z, Ye X, Huang X, Cai Y, Liu Q, Li Y, Su Z, Huang Z. 2013. Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps. PLoS One 8:e57601. doi:10.1371/journal.pone.0057601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0057601</ArticleId><ArticleId IdType="pmc">PMC3579802</ArticleId><ArticleId IdType="pubmed">23451250</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed LJ, Muench HA. 1938. A simple method for estimating fifty percent endpoints. Am J Epidemiol 27:493&#x2013;497.</Citation></Reference><Reference><Citation>Zhang JH, Chung TD, Oldenburg KR. 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:67&#x2013;73. doi:10.1177/108705719900400206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/108705719900400206</ArticleId><ArticleId IdType="pubmed">10838414</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrnes AP, Griffin DE. 1998. Binding of Sindbis virus to cell surface heparan sulfate. J Virol 72:7349&#x2013;7356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC109959</ArticleId><ArticleId IdType="pubmed">9696831</ArticleId></ArticleIdList></Reference><Reference><Citation>WuDunn D, Spear PG. 1989. Initial interaction of herpes simplex virus with cells is binding to heparan sulfate. J Virol 63:52&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC247656</ArticleId><ArticleId IdType="pubmed">2535752</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CW, Poh CL, Sam IC, Chan YF. 2013. Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor. J Virol 87:611&#x2013;620. doi:10.1128/JVI.02226-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02226-12</ArticleId><ArticleId IdType="pmc">PMC3536405</ArticleId><ArticleId IdType="pubmed">23097443</ArticleId></ArticleIdList></Reference><Reference><Citation>Haria M, Bryson HM, Goa KL. 1996. Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 51:585&#x2013;620.</Citation><ArticleIdList><ArticleId IdType="pubmed">8706596</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter M. 2005. Strategies for managing systemic fungal infection and the place of itraconazole. J Antimicrob Chemother 56(Suppl 1):i49&#x2013;i54. doi:10.1093/jac/dki224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dki224</ArticleId><ArticleId IdType="pubmed">16120634</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta AK, Chang P, Del Rosso JQ, Adam P, Hofstader SL. 1998. Onychomycosis in children: prevalence and management. Pediatr Dermatol 15:464&#x2013;471. doi:10.1046/j.1525-1470.1998.1998015464.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1525-1470.1998.1998015464.x</ArticleId><ArticleId IdType="pubmed">9875971</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta AK, Nolting S, de Prost Y, Delescluse J, Degreef H, Theissen U, Wallace R, Marynissen G, De Doncker P. 1999. The use of itraconazole to treat cutaneous fungal infections in children. Dermatology 199:248&#x2013;252. doi:10.1159/000018256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000018256</ArticleId><ArticleId IdType="pubmed">10592406</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardin TC, Graybill JR, Fetchick R, Woestenborghs R, Rinaldi MG, Kuhn JG. 1988. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 32:1310&#x2013;1313. doi:10.1128/AAC.32.9.1310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.32.9.1310</ArticleId><ArticleId IdType="pmc">PMC175857</ArticleId><ArticleId IdType="pubmed">2848442</ArticleId></ArticleIdList></Reference><Reference><Citation>Strauss DM, Glustrom LW, Wuttke DS. 2003. Towards an understanding of the poliovirus replication complex: the solution structure of the soluble domain of the poliovirus 3A protein. J Mol Biol 330:225&#x2013;234. doi:10.1016/S0022-2836(03)00577-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-2836(03)00577-1</ArticleId><ArticleId IdType="pubmed">12823963</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagappan V, Deresinski S. 2007. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 45:1610&#x2013;1617. doi:10.1086/523576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/523576</ArticleId><ArticleId IdType="pubmed">18190324</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Kojima H, Nagano T, Okabe T, Wakita T, Shimizu H. 2011. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity. J Virol 85:2364&#x2013;2372. doi:10.1128/JVI.02249-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02249-10</ArticleId><ArticleId IdType="pmc">PMC3067798</ArticleId><ArticleId IdType="pubmed">21177810</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Wakita T, Shimizu H. 2008. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. J Gen Virol 89:2518&#x2013;2530. doi:10.1099/vir.0.2008/002915-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.2008/002915-0</ArticleId><ArticleId IdType="pubmed">18796721</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren P, Zou G, Bailly B, Xu S, Zeng M, Chen X, Sheng L, Zhang Y, Guillon P, Arenzana-Seisdedos F, Buchy P, Li J, von Itzstein M, Li Q, Altmeyer R. 2014. The approved pediatric drug suramin identified as a clinical candidate for the treatment of EV71 infection&#x2014;suramin inhibits EV71 infection in vitro &amp; in vivo. Emerg Microbes Infect 3:e62. doi:10.1038/emi.2014.60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2014.60</ArticleId><ArticleId IdType="pmc">PMC4185360</ArticleId><ArticleId IdType="pubmed">26038755</ArticleId></ArticleIdList></Reference><Reference><Citation>de Repentigny L, Ratelle J, Leclerc JM, Cornu G, Sokal EM, Jacqmin P, De Beule K. 1998. Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. Antimicrob Agents Chemother 42:404&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC105422</ArticleId><ArticleId IdType="pubmed">9527794</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Kojima H, Nagano T, Okabe T, Wakita T, Shimizu H. 2013. Oxysterol-binding protein family I is the target of minor enviroxime-like compounds. J Virol 87:4252&#x2013;4260. doi:10.1128/JVI.03546-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03546-12</ArticleId><ArticleId IdType="pmc">PMC3624399</ArticleId><ArticleId IdType="pubmed">23365445</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng CL, Yeo H, Ye HQ, Liu SQ, Shang BD, Gong P, Alonso S, Shi PY, Zhang B. 2014. Inhibition of enterovirus 71 by adenosine analog NITD008. J Virol 88:11915&#x2013;11923. doi:10.1128/JVI.01207-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01207-14</ArticleId><ArticleId IdType="pmc">PMC4178731</ArticleId><ArticleId IdType="pubmed">25100827</ArticleId></ArticleIdList></Reference><Reference><Citation>Strating JR, van der Linden L, Albulescu L, Bigay J, Arita M, Delang L, Leyssen P, van der Schaar HM, Lanke KH, Thibaut HJ, Ulferts R, Drin G, Schlinck N, Wubbolts RW, Sever N, Head SA, Liu JO, Beachy PA, De Matteis MA, Shair MD, Olkkonen VM, Neyts J, van Kuppeveld FJ. 27 January 2015. Itraconazole inhibits enterovirus replication by targeting the oxysterol-binding protein. Cell Rep doi:10.1016/j.celrep.2014.12.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.12.054</ArticleId><ArticleId IdType="pmc">PMC4383725</ArticleId><ArticleId IdType="pubmed">25640182</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>